WallStreetZenWallStreetZen

NASDAQ: RNA
Avidity Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RNA

Based on 5 analysts offering 12 month price targets for Avidity Biosciences Inc.
Min Forecast
$27.00+34.53%
Avg Forecast
$44.60+122.22%
Max Forecast
$71.00+253.76%

Should I buy or sell RNA stock?

Based on 5 analysts offering ratings for Avidity Biosciences Inc.
Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RNA stock forecasts and price targets.

RNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Credit Suisse
Bottom 8%
8
BuyReiterates$35.00+74.39%2023-03-01
Chardan Capital
Top 2%
99
Strong BuyReiterates$27.00+34.53%2023-03-01
Needham
Top 21%
80
BuyReiterates$35.00+74.39%2023-03-01
Wells Fargo
Bottom 2%
2
Strong BuyMaintains$55.00+174.04%2023-01-04
Raymond James
Bottom 26%
26
Strong BuyMaintains$71.00+253.76%2022-12-15
Anonymous
SVB Leerink
BuyMaintains$50.00+149.13%2022-05-11

1 of 1

Forecast return on equity

Is RNA forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is RNA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

RNA earnings per share forecast

What is RNA's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$3.78
Avg 2 year Forecast
-$3.98
Avg 3 year Forecast
-$2.96

RNA revenue forecast

What is RNA's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$7.7M-16.84%
Avg 2 year Forecast
$2.9M-68.79%
Avg 3 year Forecast
$278.1M+2,914.74%
RNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNA revenue growth forecast

How is RNA forecast to perform vs Biotechnology companies and vs the US market?
Company
190.26%
Industry
40.95%
Market
8.76%
RNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNA$20.07$44.60+122.22%Strong Buy
IOVA$6.33$20.27+220.27%Buy
VCEL$29.94$33.00+10.22%Hold
RCKT$17.67$49.00+177.31%Strong Buy
KDNY$22.05$39.33+78.38%Strong Buy
View Top Biotech Stocks

Avidity Biosciences Stock Forecast FAQ

Is Avidity Biosciences Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: RNA) stock is to Strong Buy RNA stock.

Out of 5 analysts, 3 (60%) are recommending RNA as a Strong Buy, 2 (40%) are recommending RNA as a Buy, 0 (0%) are recommending RNA as a Hold, 0 (0%) are recommending RNA as a Sell, and 0 (0%) are recommending RNA as a Strong Sell.

If you're new to stock investing, here's how to buy Avidity Biosciences stock.

What is RNA's earnings growth forecast for 2023-2025?

(NASDAQ: RNA) Avidity Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Avidity Biosciences's earnings in 2023 is -$173,995,000.On average, 4 Wall Street analysts forecast RNA's earnings for 2023 to be -$267,654,138, with the lowest RNA earnings forecast at -$345,542,908, and the highest RNA earnings forecast at -$233,666,311. On average, 2 Wall Street analysts forecast RNA's earnings for 2024 to be -$281,815,733, with the lowest RNA earnings forecast at -$349,083,307, and the highest RNA earnings forecast at -$215,256,238.

In 2025, RNA is forecast to generate -$209,591,600 in earnings, with the lowest earnings forecast at -$209,591,600 and the highest earnings forecast at -$209,591,600.

What is RNA's revenue growth forecast for 2023-2026?

(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 190.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Avidity Biosciences's revenue in 2023 is $9,224,000.On average, 3 Wall Street analysts forecast RNA's revenue for 2023 to be $543,167,961, with the lowest RNA revenue forecast at $389,443,852, and the highest RNA revenue forecast at $815,353,809. On average, 1 Wall Street analysts forecast RNA's revenue for 2024 to be $203,856,154, with the lowest RNA revenue forecast at $203,856,154, and the highest RNA revenue forecast at $203,856,154.

In 2026, RNA is forecast to generate $19,690,281,132 in revenue, with the lowest revenue forecast at $19,690,281,132 and the highest revenue forecast at $19,690,281,132.

What is RNA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: RNA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is RNA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year RNA price target, the average RNA price target is $44.60, with the highest RNA stock price forecast at $71.00 and the lowest RNA stock price forecast at $27.00.

On average, Wall Street analysts predict that Avidity Biosciences's share price could reach $44.60 by Mar 1, 2024. The average Avidity Biosciences stock price prediction forecasts a potential upside of 122.22% from the current RNA share price of $20.07.

What is RNA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: RNA) Avidity Biosciences's current Earnings Per Share (EPS) is -$3.34. On average, analysts forecast that RNA's EPS will be -$3.78 for 2023, with the lowest EPS forecast at -$4.88, and the highest EPS forecast at -$3.30. On average, analysts forecast that RNA's EPS will be -$3.98 for 2024, with the lowest EPS forecast at -$4.93, and the highest EPS forecast at -$3.04. In 2025, RNA's EPS is forecast to hit -$2.96 (min: -$2.96, max: -$2.96).

What is RNA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: RNA) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.